Neurocrine Biosciences, Inc. (NBIX) stock saw a decline, ending the day at $119.85 which represents a decrease of $-2.46 or -2.01% from the prior close of $122.31. The stock opened at $123 and touched ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit at 11:00 a.m. Eastern Time on Thursday, September 26, 2024.

We recently compiled a list of the 10 Best Aggressive Growth Stocks to Buy According to Hedge Funds. In this article, we are ...

Neurocrine Biosciences has reported that its Phase II ERUDITE clinical trial of luvadaxistat did not achieve its primary ...

Neurocrine Biosciences announced that its ERUDITE Phase 2 trial for luvadaxistat failed to meet its primary endpoint in ...

Neurocrine Biosciences’ schizophrenia program pivot has failed. | Neurocrine Biosciences’ schizophrenia program pivot has ...

Neurocrine Biosciences (NBIX) has halted development of luvadaxistat due to disappointing results from a Phase 2 study of the ...

BMO Capital Markets analyst Evan Seigerman said luvadaxistat’s inconsistencies between mid-stage trials raise questions about ...

Sept 12 (Reuters) - Neurocrine Biosciences (NBIX.O), opens new tab said on Thursday it will halt the development of its experimental drug, aimed at improving cognitive function in patients with ...

LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VYGR), a biotechnology company dedicated to advancing ...

Neurocrine Biosciences, Inc. (NBIX) stock saw a decline, ending the day at $120.17 which represents a decrease of $-1.04 or -0.86% from the prior close of $121.21. The stock opened at $122.2 and ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $168.74, with a high estimate of $219.00 and a low estimate of $128.00. Marking an increase ...